The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology.
about
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptorsLigand-directed signalling at beta-adrenoceptorsIdentification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptorAre there functional β₃-adrenoceptors in the human heart?Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.Differential regulation of two palmitoylation sites in the cytoplasmic tail of the beta1-adrenergic receptorImpact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor.Atypical pharmacologies at beta-adrenoceptors.Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chainChronic activation of the low affinity site of β1-adrenoceptors stimulates haemodynamics but exacerbates pressure-overload cardiac remodelling.Adrenergic nervous system in heart failure: pathophysiology and therapy.Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors.Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human β1-adrenoceptor expressed in HEK-293 cells.Metabolic responses to BRL37344 and clenbuterol in soleus muscle and C2C12 cells via different atypical pharmacologies and beta2-adrenoceptor mechanismsDifferent β-adrenoceptor subtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels.Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.Negative cooperativity across β1-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 β1-adrenoceptor binding conformation.Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.Detection of the secondary, low-affinity β1 -adrenoceptor site in living cells using the fluorescent CGP 12177 derivative BODIPY-TMR-CGP.Can [I]-Iodocyanopindolol Label β(3)-Adrenoceptors in Rat Urinary Bladder?The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor.Homology model and docking studies on porcine β₂ adrenoceptor: description of two binding sites.The antihypertensive drug pindolol attenuates long-term but not short-term binge-like ethanol consumption in mice.Upregulation of β3-adrenergic receptor expression in the atrium of rats with chronic heart failure.Autoantibodies against cardiac β(1)-adrenoceptor do not affect the low-affinity state β(1)-adrenoceptor-mediated inotropy in rat cardiomyocytes.
P2860
Q28476391-E56C9382-B89C-49CD-BDCB-2B5E772427EBQ33730592-D931C6B4-34DA-4618-93E7-83618D067DB4Q34042126-2AFAC77A-4822-474D-843D-2B39A5B3526AQ34588651-558747BC-2F1B-4D70-95AC-15DB32BB8294Q34588659-AA8A85EE-8E3E-4C33-8C16-E9DBA0F33382Q34837191-747A6DC3-C548-4A5F-A623-17101FAEF75EQ34998252-0151320D-8FA7-440E-89C2-3EFC0511492BQ35046547-234E6F00-F9B4-4D71-A766-DDF1FAF021DEQ36938463-86D6AC1F-CF37-4938-95A8-27E5E672003BQ37239720-A8651799-2049-4AA2-9945-AE1B77325202Q37327391-3D1256A5-4DC0-404A-B545-A42A1AEDD97BQ37349756-C84CA54D-FC23-47DC-A068-4CB2509AE586Q38641723-89B95C47-FF76-42B5-96E4-3D7499010D69Q39428983-4F4DA8F9-D259-49DF-B8E7-BF64E0AFFB74Q39972489-9D8F7126-B112-47E3-A48A-19F5AED7BE99Q40638841-C40AC475-7B4B-4248-9177-4B8A244CA303Q41571207-C3D9B468-C11A-4EB8-AF56-8BB0B96D4341Q42149596-787A40A2-9BC1-498C-9E80-FD494941F052Q42191909-04E42931-0DA3-4DDA-9BB7-3D87F8D3BBB5Q42429572-13D0F571-00D7-4C09-9A11-1C7AD6A868E0Q42559814-7DD51A80-014A-4823-B759-3072F2FC2DFCQ42730907-6E348322-DDD8-4B9F-A8EF-B94A461E3BAAQ42759842-637B23CF-3206-4BE2-88A3-32C4D03314A7Q44530514-178EE9FD-433E-419F-B43F-5B5CBA274FE7Q48690330-B55DBF94-484E-4150-8F89-ECA65F1462C6Q50502980-1F246831-4280-4832-9757-4C1F5A415A9AQ54557679-B876915C-42AD-4EFA-89D0-B97B85323010
P2860
The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The low-affinity site of the b ...... o cardiovascular pharmacology.
@en
The low-affinity site of the b ...... o cardiovascular pharmacology.
@nl
type
label
The low-affinity site of the b ...... o cardiovascular pharmacology.
@en
The low-affinity site of the b ...... o cardiovascular pharmacology.
@nl
prefLabel
The low-affinity site of the b ...... o cardiovascular pharmacology.
@en
The low-affinity site of the b ...... o cardiovascular pharmacology.
@nl
P1476
The low-affinity site of the b ...... o cardiovascular pharmacology.
@en
P2093
Alberto J Kaumann
Peter Molenaar
P304
P356
10.1016/J.PHARMTHERA.2008.03.009
P577
2008-04-11T00:00:00Z